Please select the option that best describes you:
Topics:
Hematologic Malignancies • Medical Oncology • Lymphoma • Non-Hodgkin Lymphoma • CAR-T • Hematology • DLBCL
What are your practical considerations for incorporating bispecific antibody therapy into treatment of relapsed DLBCL?
Answer from: Medical Oncologist at Academic Institution
In relapsed/refractory DLBCL, if the patient has not yet received bispecific antibody (BsAb) and/or CAR T-cells, and the patient is eligible and able to receive CAR T-cells, I favor CAR T-cells before BsAb, given extensive follow-up time demonstrating CAR T-cells are a potentially curative approach ...
Sign In or Register to read more
Answer from: Medical Oncologist at Academic Institution
The practical considerations for incorporating bispecific antibodies into the treatment of relapsed DLBCL is the awareness of the potential side effects, although less than CAR T-cell therapy, in regards to the risk of cytokine release syndrome (CRS) and immune-effector cell associated neurotoxicity...
Answer from: at Academic Institution
CD20xCD3 bispecific antibodies are a very promising class of drugs available for relapsed DLBCL, with response rates ~50-60% as monotherapy and approaching 70% in combination with chemotherapy (GemOx). Glofitamab or epcoritamab in combination with GemOx is available in the 2nd-line setting if the pa...
Answer from: Medical Oncologist at Community Practice
Bispecific antibodies are a very effective class of agents for lymphoma, including relapsed DLBCL. However, it is unclear whether they offer curative-intent therapy, and so I still typically sequence CAR T prior to bispecific antibodies, except in cases where patients absolutely cannot receive CAR T...